Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 139

2.

Randomised trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: results at six months. The EPIC Investigators.

Topol EJ, Califf RM, Weisman HF, Ellis SG, Tcheng JE, Worley S, Ivanhoe R, George BS, Fintel D, Weston M, et al.

Lancet. 1994 Apr 9;343(8902):881-6.

PMID:
7908357
3.

Safety and efficacy of the platelet glycoprotein IIb/IIIa inhibitor abciximab in Chinese patients undergoing high-risk angioplasty.

Chen YH, Chen JW, Wu TC, Ding PY, Wang SP, Chang MS.

Zhonghua Yi Xue Za Zhi (Taipei). 2000 Jan;63(1):8-15.

PMID:
10645045
4.

Increased risk of non-Q wave myocardial infarction after directional atherectomy is platelet dependent: evidence from the EPIC trial. Evaluation of c7E3 for the Prevention of Ischemic Complications.

Lefkovits J, Blankenship JC, Anderson KM, Stoner GL, Talley JD, Worley SJ, Weisman HF, Califf RM, Topol EJ.

J Am Coll Cardiol. 1996 Oct;28(4):849-55.

5.
7.
8.
10.
11.

Randomized trial of a GPIIb/IIIa platelet receptor blocker in refractory unstable angina. European Cooperative Study Group.

Simoons ML, de Boer MJ, van den Brand MJ, van Miltenburg AJ, Hoorntje JC, Heyndrickx GR, van der Wieken LR, de Bono D, Rutsch W, Schaible TF, et al.

Circulation. 1994 Feb;89(2):596-603.

PMID:
7508826
13.

Economic assessment of platelet glycoprotein IIb/IIIa inhibition for prevention of ischemic complications of high-risk coronary angioplasty. EPIC Investigators.

Mark DB, Talley JD, Topol EJ, Bowman L, Lam LC, Anderson KM, Jollis JG, Cleman MW, Lee KL, Aversano T, Untereker WJ, Davidson-Ray L, Califf RM.

Circulation. 1996 Aug 15;94(4):629-35.

16.

An overview of the results of the EPIC trial.

Califf RM, Lincoff AM, Tcheng JE, Topol EJ.

Eur Heart J. 1995 Nov;16 Suppl L:43-9.

PMID:
8869018
17.

Sustained suppression of ischemic complications of coronary intervention by platelet GP IIb/IIIa blockade with abciximab: one-year outcome in the EPILOG trial. Evaluation in PTCA to Improve Long-term Outcome with abciximab GP IIb/IIIa blockade.

Lincoff AM, Tcheng JE, Califf RM, Kereiakes DJ, Kelly TA, Timmis GC, Kleiman NS, Booth JE, Balog C, Cabot CF, Anderson KM, Weisman HF, Topol EJ.

Circulation. 1999 Apr 20;99(15):1951-8.

18.

Pharmacodynamics of chimeric glycoprotein IIb/IIIa integrin antiplatelet antibody Fab 7E3 in high-risk coronary angioplasty.

Tcheng JE, Ellis SG, George BS, Kereiakes DJ, Kleiman NS, Talley JD, Wang AL, Weisman HF, Califf RM, Topol EJ.

Circulation. 1994 Oct;90(4):1757-64.

PMID:
7923659
19.

Shear-induced platelet aggregation is inhibited by in vivo infusion of an anti-glycoprotein IIb/IIIa antibody fragment, c7E3 Fab, in patients undergoing coronary angioplasty.

Konstantopoulos K, Kamat SG, Schafer AI, BaƱez EI, Jordan R, Kleiman NS, Hellums JD.

Circulation. 1995 Mar 1;91(5):1427-31.

20.

Bleeding complications with the chimeric antibody to platelet glycoprotein IIb/IIIa integrin in patients undergoing percutaneous coronary intervention. EPIC Investigators.

Aguirre FV, Topol EJ, Ferguson JJ, Anderson K, Blankenship JC, Heuser RR, Sigmon K, Taylor M, Gottlieb R, Hanovich G, et al.

Circulation. 1995 Jun 15;91(12):2882-90.

Supplemental Content

Support Center